Next-generation TGF-β2-targeting ASO enhanced through chemical modifications, demonstrating improved mRNA binding affinity and plasma stability for cancer treatment.
Sequence-specific mRNA binding enables selective suppression of TGF-β2 expression, offering therapeutic potential in tumors with TGF-β2 overexpression while minimizing adverse effects associated with broad TGF-β pathway inhibition.
Demonstrated safety in non-clinical studies and cleared to initiate a Phase 1 clinical trial in Australia.
ATB-720
Immune-Modulating ASO for Skin Diseases
First-in-class CHI3L1-targeting ASO for inflammatory skin diseases and skin cancer.
Discovered using the AI-driven ASODE™ platform, enabling rapid and efficient ASO hit and lead generation.
High-permeability topical formulation established, with further optimization in progress.
Demonstrated superior efficacy and safety in animal models of atopic dermatitis and psoriasis, outperforming standard-of-care treatments.
Engineered for topical delivery to minimize systemic and off-target exposure, particularly in the liver and kidney, often seen with injectable ASOs.
ATB-810
Immune-Modulating ASO for Neurodegenerative Diseases
First-in-class CHI3L1-targeting ASO in development for neurodegenerative diseases.
Utilizes C-Duplex™ technology, which improves brain distribution of ASOs and extends dosing intervals.
Inhibits CHI3L1 mRNA expression and protein secretion in brain cells.
Demonstrated reduced CHI3L1 expression and decreased p-TDP-43 levels, a key pathological marker of amyotrophic lateral sclerosis (ALS), in an ALS organoid model.
Improved brain distribution of ASOs through C-Duplex™ technology confirmed in animal studies.
